Page 37 - Aintained News Today

Initially Neutral on the company, JP Morgans analyst Chetan Udeshi maintained his recommendation. The target price continues to be set at EUR 40. | April 13, 2023

In a research note, UBS analyst Patrick Hummel has maintained his recommendation on the stock with a Buy rating. The target price is still set at EUR 85. | April 13, 2023

In a research note, UBS analyst Patrick Hummel has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged at EUR 6.20. | April 13, 2023

In a research note, JP Morgan analyst Chetan Udeshi has maintained his recommendation on the stock with a Buy rating. The target price is still set at EUR 55. | April 13, 2023

In a research note, JP Morgan analyst Chetan Udeshi has maintained his recommendation on the stock with a Buy rating. The target price is unchanged and still at EUR 26. | April 13, 2023

In a research note, Jefferies analyst Kathryn Parker has maintained his recommendation on the stock with a Neutral rating. The target price remains unchanged at EUR 69. | April 13, 2023

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically... | April 12, 2023

In a research note, JP Morgan analyst Toby Ogg has maintained his recommendation on the stock with a Buy rating. The target price has been lifted and is now set at EUR 137 compared to EUR 117 before. | April 12, 2023

Initially Neutral on the company, RBCs analyst Nick Housden maintained his recommendation. The target price is unchanged at SEK 201. | April 12, 2023

In a research note, RBC analyst Piral Dadhania has maintained his recommendation on the stock with a Buy rating. The target price continues to be set at EUR 925. | April 12, 2023